The mystery of the ketogenic diet: benevolent pseudo-diabetes

Mikhail V. Blagosklonny

Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, NY, USA

ABSTRACT
Designed a century ago to treat epilepsy, the ketogenic diet (KD) is also effective against obesity and diabetes. Paradoxically, some studies in rodents have found that the KD seemingly causes diabetes, contradicting solid clinical data in humans. This paradox can be resolved by applying the concept of starvation pseudo-diabetes, which was discovered in starved animals almost two centuries ago, and has also been observed in some rapamycin-treated rodents. Intriguingly, use of the KD and rapamycin is indicated for a similar spectrum of diseases, including Alzheimer’s disease and cancer. Even more intriguingly, benevolent (starvation) pseudo-diabetes may counteract type 2 diabetes or its complications.

ARTICLE HISTORY
Received 28 June 2019
Accepted 11 July 2019

KEYWORDS
Ketogenic diet; aging; rapamycin; rapalogs; mTOR; fasting

Introduction
A number of publications have alarmingly warned that the ketogenic diet (KD), or low carbohydrate-high fat (LC-HF) diet, may have detrimental metabolic effects that lead to the development of diabetes. For example, one study stated that “Long-term high-fat, low-carbohydrate KD leads to features that are also associated with the metabolic syndrome and an increased risk for type 2 diabetes in humans” [1]. Two other studies reported that “Use of LC-HF diets … should be balanced against potentially harmful metabolic side effects” [2] and that “Our results do not support the recommendation of an LCHFD for use in prediabetes [3]. Moreover, based on that last study, the news media reported to the public that “Following a low-carbohydrate, high-fat diet for just eight weeks can lead to rapid weight gain and health complications, a new mouse study has demonstrated. The study has prompted researchers to issue a warning about putting faith in so-called fad diets.” Furthermore, the news title was alarming: “Paleo diet is dangerous, increases weight gain, diabetes expert warns.” <www.sciencedaily.com/releases/2016/02/160218114753.htm> . It is noteworthy that these conclusions were based on mouse studies, which, as has been discussed, are irrelevant to humans [4,5]. But how can we explain the discrepancy between the clinical results from humans and the experimental results from mice? And are these metabolic alterations actually detrimental to the health of the mice?

The KD in brief
KDs are typically LC-HF diets, which cause ketosis (elevated blood levels of ketones namely acetoacetic acid and beta-hydroxybutyric acid) [6–13]. In the absence of glucose, the brain metabolizes ketones [6,13,14], which are produced in the liver from fatty acids and serve as substitutes for glucose as an energy source. The numerous variants of the KD are not well defined. For example, the distinction between a “ketogenic” diet and the Atkins diet is meaningless because Atkins diet is also a KD. The definition of a KD is a diet that causes ketosis, such as one that is low in carbohydrate (e.g. < 20 grams) and usually low in calories. Ketosis can be induced without fat consumption. As a striking example, complete fasting reliably induces ketosis after 1–3 days. In practice, KDs entail consumption of less than 20 grams of carbohydrates, regardless of fat and caloric intake [6,15]. There are numerous abbreviations that are used for KDs, including LC-HF, VLCKD (very low-calorie-ketogenic), and LCKD (low-carbohydrate ketogenic diet). Whenever possible, we will abbreviate them as KDs.
1. Kds are used to treat obesity and diabetes in humans

KDs are successfully being used in the treatment of obesity, non-alcoholic fatty liver disease, neurological diseases and cancer [6,7,9–11,16]. They are also being used in the treatment of type 2 diabetes [8,9,11–13,17–23]. When consuming the same numbers of calories, KDs are more effective than standard calorie restrictive diets for body weight reduction and improvement of glycemic control in diabetic patients [24–28], and enable discontinuation or reduction of medications in some diabetic patients [18,27,29]. In one study, for example, fat-free KDs (100 g/day protein and no fat/carbohydrates) enabled insulin discontinuation after one week in most patients [30].

2. Self-contradictory results in rodents

KDs extend the lifespan of adult mice [31,32]. Even a cyclic (alternated weekly) KD improves survival, health and memory in aged mice [33]. These results argue against KDs having detrimental effects. Typically, the KD induces a unique metabolic state associated with improved glucose tolerance and weight loss [34].

In ob/ob mice, a KD even improves glucose tolerance independently of weight loss [35]. Remarkably, the KD reverses diabetic nephropathy in two mouse models of diabetes [36]. The results of these studies are consistent with the clinical data.

On the other hand, a number of studies report that KDs have diabetogenic effects. It was found that, despite preventing weight gain in mice, the KD induces insulin resistance [37]. In addition, it was later shown that the KD causes glucose intolerance without weight loss in mice [1], and even increases weight gain and glucose intolerance in New Zealand Obese mice [3]. Other studies also reported insulin resistance and glucose intolerance in rodents fed a KD [1,2,38–42].

3. Starvation-induced pseudo-diabetes

Claude Bernard (in 1846) and W. L. Lehmann (in 1874) independently described “starvation diabetes” in rabbits and dogs during prolonged fasting [43,44]. When fasted animals are fed “a good meal with an abundance of carbohydrate, glucose will appear in the urine” [43]. This condition was named starvation pseudo-diabetes [43,44]. Starvation or prolonged fasting decreases insulin levels and causes insulin resistance as a compensatory response aimed at saving glucose for the brain. (Note: Low insulin secretion and insulin resistance are manifested as glucose intolerance – i.e., hyperglycemia and even glycosuria – after re-introducing carbohydrates). In addition, glucose is produced from certain amino acids in the liver (gluconeogenesis), which also produces ketone bodies from fatty acids (ketogenesis). Eventually, the ketones substitute for glucose as the main fuel for the brain. Ketosis is a prominent feature of prolonged fasting or starvation.

But achieving the beneficial effects of pseudo-diabetes does not require complete fasting; any severe carbohydrate/calorie restrictions can yield the same effects. For example, healthy volunteers practicing severe calorie restriction develop “diabetic-like” glucose intolerance; nonetheless, calorie restriction improves health in humans and prevents type 2 diabetes [45,46]. As summarized in 1945, “the phenomenon of starvation diabetes has been repeatedly reported in one connection or another” [44]. As a more recent example, Koffler et al. rediscovered starvation diabetes during a strenuous weight reduction and warned about its detrimental effects [47]. Glucose intolerance caused by low-carbohydrate diet was suggested to be a physiological state [48].

4. Kd-induced pseudo-diabetes in rodents

Ketosis is a prominent feature of KDs and diabetes. In several rodent studies, the KD caused insulin resistance, glucose intolerance [1,2,38–40], and even dyslipidemia and pro-inflammatory effects [1,49]. This combination of insulin-resistance, glucose intolerance, lipolysis, gluconeogenesis, ketosis and ketonuria matches the description of starvation pseudo-diabetes. In rodents fed a KD, pseudo-diabetes is reversed upon cessation of the KD [38]. In a human study ketosis caused glucose intolerance in overweight non-diabetic subjects [50].

5. Rapamycin-induced pseudo-diabetes

As recently as 2019, it was warned that “the side effects associated with long-term rapamycin treatment ... seemed to preclude the routine use of rapamycin as
a therapy for age-related diseases” [51]. I disagree. It is not the side effects in rodents, per se, but such warnings that have halted the use of rapamycin for life extension. Still, rapamycin and its analog, everolimus, have already been studied for the prevention and treatment of age-related diseases [52], potentially giving humans a chance to live longer and healthier lives in our lifetime. [See the forthcoming article “The fear of immortality: but it is more dangerous not to use anti-aging drugs than to use them”].

Rapamycin, an inhibitor of the nutrient-sensing mTOR pathway, is a calorie-restriction mimetic [53–55]. It is therefore predictable that rapamycin may cause conditions resembling starvation pseudo-diabetes in some rodent models [56–58]. This condition was misinterpreted as a deleterious side effect, despite the increased longevity of rapamycin-fed mice [59]. A “side effect” that is associated with life extension is not so detrimental after all.

Like KDs, rapamycin may increase or decrease insulin resistance, depending on the treatment duration and the specific model being studied [See the forthcoming article “Fasting and rapamycin: diabetes versus benevolent hyperglycemia”]. Rapamycin prevents insulin resistance caused by nutrient infusion in humans [60] and decreases insulin resistance in diabetic rodents [61–64]. In both rats and mice, rapamycin (sirolimus) prevents diabetic nephropathy [65–77]. In numerous independent studies, rapamycin was found to prolong life in a variety of mouse strains (see for references [78–81]). Rapamycin also improved metabolic functioning in non-human primates [82], and no symptoms of pseudo-diabetes were observed in relatively healthy elderly and healthy volunteers [83–87].

6. Benevolent pseudo-diabetes prevents type 2 diabetes

Rapamycin-induced metabolic alterations are reversible and even benevolent [63,79,88–92]. For example, despite hyperglycemia, rapamycin ameliorates nephropathy in a mouse model of type 2 diabetes [75]. Fasting, which causes starvation pseudo-diabetes, has been successfully used for the prevention and treatment of type 2 diabetes. A very low calorie diet prevents and reverses diabetes, especially at its early stages [46,93–99]. As mentioned above, Fontana et al found that severe calorie restriction may cause insulin resistance in some human subjects, and they insightfully suggested that this kind of “insulin resistance” slows aging in mice [45]. Although animals fed a KD may exhibit glucose intolerance, they differ from diabetes patients in part because they are healthy [40].

KDs, which cause benevolent pseudo-diabetes, are effective for the prevention and treatment of type 2 diabetes in humans. In a remarkable study of healthy people, ketonuria after spontaneous (overnight) fasting was associated with a reduced risk of diabetes. Indeed, Kim et al suggested that spontaneous ketosis may prevent the development of diabetes [100]. Ketogenesis is suppressed in aged mice and rapamycin increases ketone production [101]. Also, metformin increases blood levels of beta-hydroxybutyrate and alpha-ketoglutarate in cancer patients [102]. Remarkably, alpha-ketoglutarate inhibits MTOR and extends lifespan in Drosophila [103].

7. Conclusion

KDs have been safely used for many years by millions of humans to treat obesity and diabetes. Like fasting, KDs may cause the symptoms of starvation pseudo-diabetes especially in some rodent models, but starvation pseudo-diabetes is beneficial and is not type 2 diabetes. In fact, it may counteract type 2 diabetes. Starvation pseudo-diabetes is associated with deactivation of mTOR, whereas type 2 diabetes is associated with hyperactivation of mTOR [57]. Thus, the warning that KD may cause type 2 diabetes in humans is not justified and contradicts what is observed in clinical practice. Nearly identical warnings have halted development of rapamycin and everolimus as antiaging drugs. Of course, caution is necessary, as rodent research indicates, but it should be recognized that excessive caution may preclude medical options that are already being safely used in humans.

Acknowledgments

I thank George Henderson (Auckland Univ., New Zealand), Richard Veech (NIH, USA), Rennan de Oliveira Caminhoto (Univ. São Paulo, Brazil), Jon Ramsey (University of California, USA) for helpful comments.
Disclosure statement
No potential conflict of interest was reported by the author.

References

[1] Ellenbroek JH, van Dijck L, Tons HA, et al. Long-term ketogenic diet causes glucose intolerance and reduced beta- and alpha-cell mass but no weight loss in mice. Am J Physiol Endocrinol Metab. 2014;306(5):E552–558.
[2] Bielohuby M, Sisley S, Sandoval D, et al. Impaired glucose tolerance in rats fed low-carbohydrate, high-fat diets. Am J Physiol Endocrinol Metab. 2013;305(9):E1059–1070.
[3] Lamont BJ, MF W, Andrikopoulos S. A low-carbohydrate high-fat diet increases weight gain and does not improve glucose tolerance, insulin secretion or beta-cell mass in NZO mice. Nutr Diabetes. 2016:e194.
[4] Schofield G, Henderson G, Crofts C, et al. What are we to think when results from mouse research contradict those from human experiments and clinical practice? Nutr Diabetes. 2016;6(8):e224.
[5] Caminhotto RO, Lima FB. Low carbohydrate high fat diets: when models do not match reality. Arch Endocrinol Metab. 2016;60(4):405–406.
[6] Paoli A, Rubini A, Volek JS, et al. Beyond weight loss: a review of the therapeutic uses of very-low-carbohydrate (ketogenic) diets. Eur J Clin Nutr. 2013;67(8):789–796.
[7] CE S, JM R. The ketogenic diet as a treatment paradigm for diverse neurological disorders. Front Pharmacol. 2012;3:59.
[8] Mobbs CV, Mastaitis J, Isoda F, et al. Treatment of diabetes and diabetic complications with a ketogenic diet. J Child Neurol. 2013;28(8):1009–1014.
[9] Branco AF, Ferreira A, Simoes RF, et al. Ketogenic diets: from cancer to mitochondrial diseases and beyond. Eur J Clin Invest. 2016;46(3):285–298.
[10] HY C, YK P, Rationale F. Acceptability of ketogenic diet for cancer treatment. J Cancer Prev. 2017;22(3):127–134.
[11] Gibas MK, Gibas KJ. Induced and controlled dietary ketosis as a regulator of obesity and metabolic syndrome pathologies. Diabetes Metab Syndr. 2017;11(Suppl 1):S385–S390.
[12] Magnusdottir OK, Gunnarsdottir I, BE B. Dietary guidelines in type 2 diabetes: the nordic diet or the ketogenic diet? Curr Opin Endocrinol Diabetes Obes. 2017;24(5):315–319.
[13] Walczyk T, JY W. The ketogenic diet: making a comeback. Consult Pharm. 2017;32(7):388–396.
[14] Owen OE, Morgan AP, Kemp HG, et al. Brain metabolism during fasting. J Clin Invest. 1967;46(10):1589–1595.
[15] Dashti HM, Al-Zaid NS, Mathew TC, et al. Long term effects of ketogenic diet in obese subjects with high cholesterol level. Mol Cell Biochem. 2006;286(1–2):1–9.
[16] Weber DD, Aminazdeh-Gohari S, Ko[a]rler B. Ketogenic diet in cancer therapy. Aging (Albany NY). 2018;10(2):164–165.
[17] Gumbiner B, JA W, MP M. Effects of diet composition and ketosis on glycemia during very-low-energy-diet therapy in obese patients with non-insulin-dependent diabetes mellitus. Am J Clin Nutr. 1996;63(1):110–115.
[18] Yancy WS Jr., Foy M, Chalecki AM, et al. A low-carbohydrate, ketogenic diet to treat type 2 diabetes. Nutr Metab (Lond). 2005;2:34.
[19] Accurso A, Bernstein RK, Dahlqvist A, et al. Dietary carbohydrate restriction in type 2 diabetes mellitus and metabolic syndrome: time for a critical appraisal. Nutr Metab (Lond). 2008;5:9.
[20] JV N, EA J. Low-carbohydrate diet in type 2 diabetes: stable improvement of bodyweight and glycemic control during 44 months follow-up. Nutr Metab (Lond). 2008;5:14.
[21] Volek JS, Phinney SD, Forsythe CE, et al. Carbohydrate restriction has a more favorable impact on the metabolic syndrome than a low fat diet. Lipids. 2009;44(4):297–309.
[22] Hussain TA, Mathew TC, Dashti AA, et al. Effect of low-calorie versus low-carbohydrate ketogenic diet in type 2 diabetes. Nutrition. 2012;28(10):1016–1021.
[23] Westman EC, Tondt J, Maguire E, et al. Implementing a low-carbohydrate, ketogenic diet to manage type 2 diabetes mellitus. Expert Rev Endocrinol Metab. 2018;13(5):263–272.
[24] Goday A, Bellido D, Sajoux I, et al. Short-term safety, tolerability and efficacy of a very low-calorie-ketogenic diet interventional weight loss program versus hypocaloric diet in patients with type 2 diabetes mellitus. Nutr Diabetes. 2016;6(9):e230.
[25] Westman EC, Yancy WS Jr., Mavropoulos JC, et al. The effect of a low-carbohydrate, ketogenic diet versus a low-glycemic index diet on glycemic control in type 2 diabetes mellitus. Nutr Metab (Lond). 2008;5:36.
[26] Moreno B, Bellido D, Sajoux I, et al. Comparison of a very low-calorie-ketogenic diet with a standard low-calorie diet in the treatment of obesity. Endocrine. 2014;47(3):793–805.
[27] Samaha FF, Iqbal N, Seshadri P, et al. A low-carbohydrate as compared with a low-fat diet in severe obesity. N Engl J Med. 2003;348(21):2074–2081.
[28] Bueno NB, de Melo IS, de Oliveira SL, et al. Very-low-carbohydrate ketogenic diet v. low-fat diet for long-term weight loss: a meta-analysis of randomised controlled trials. Br J Nutr. 2013;110(7):1178–1187.
[29] Foster GD, Wyatt HR, Hill JO, et al. A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med. 2003;348(21):2082–2090.
[30] Bistrian BR, Blackburn GL, Flatt JP, et al. Nitrogen metabolism and insulin requirements in obese diabetic adults on a protein-sparing modified fast. Diabetes. 1976;25(6):494–504.

[31] Roberts MN, Wallace MA, Tomilov AA, et al. A ketogenic diet extends longevity and healthspan in adult mice. Cell Metab. 2017;26(3):539–546 e535.

[32] Veech RL, Bradshaw PC, Clarke K, et al. Ketone bodies mimic the life span extending properties of caloric restriction. IUBMB Life. 2017;69(5):305–314.

[33] Newman JC, Covarrubias AJ, Zhao M, et al. Ketogenic diet reduces midlife mortality and improves memory in aging mice. Cell Metab. 2017;26(3):547–557 e548.

[34] Kennedy AR, Pissios P, Otu H, et al. A high-fat, ketogenic diet induces a unique metabolic state in mice. Am J Physiol Endocrinol Metab. 2007;292(6):E1724–1739.

[35] Badman MK, Kennedy AR, Adams AC, et al. A very low carbohydrate ketogenic diet improves glucose tolerance in ob/ob mice independently of weight loss. Am J Physiol Endocrinol Metab. 2009;297(5):E1197–1204.

[36] Poplawski MM, Mastaitis JW, Isoda F, et al. Reversal of diabetic nephropathy by a ketogenic diet. PLoS One. 2011;6(4):e18604.

[37] Jornayvaz FR, Jurczak MJ, Lee HY, et al. A high-fat, ketogenic diet causes hepatic insulin resistance in mice, despite increasing energy expenditure and preventing weight gain. Am J Physiol Endocrinol Metab. 2010;299(5):E808–815.

[38] Kinzig KP, Honors MA, Hargrave SL. Insulin sensitivity and glucose tolerance are altered by maintenance on a ketogenic diet. Endocrinology. 2010;151(7):3105–3114.

[39] Schugar RC, Crawford PA. Low-carbohydrate ketogenic diets, glucose homeostasis, and nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care. 2012;15(4):374–380.

[40] Grandl G, Straub L, Rudigier C, et al. Short-term feeding of a ketogenic diet induces more severe hepatic insulin resistance than an obesegenic high-fat diet. J Physiol. 2018;596(19):4597–4609.

[41] Murata Y, Nishio K, Mochiyama T, et al. Fgf21 impairs adipocyte insulin sensitivity in mice fed a low-carbohydrate, high-fat ketogenic diet. PLoS One. 2013;8(7):e69330.

[42] Medak KD, Townsend LK. Adding more fat to a high-fat diet only exacerbates hepatic insulin resistance. J Physiol. 2019;597(6):1435–1436.

[43] Lundbaek K. Metabolic abnormalities in starvation diabetes. Yale J Biol Med. 1948;20(6):533–544.

[44] Peters JP. Starvation diabetes, the reason for the use of glucose in the treatment of diabetic acidosis. Yale J Biol Med. 1945;17(6):705–726.

[45] Fontana L, Klein S, Holloszy JO. Effects of long-term calorie restriction and endurance exercise on glucose tolerance, insulin action, and adipokine production. Age (Dordr). 2010;32(1):97–108.

[46] Most J, Tosti V, Redman LM, et al. Calorie restriction in humans: an update. Ageing Res Rev. 2017;39:36–45.

[47] Koffler M, Kisch ES. Starvation diet and very-low-calorie diets may induce insulin resistance and overt diabetes mellitus. J Diabetes Complications. 1996;10(2):109–112.

[48] Caminhotto Rde O, FB L. Impaired glucose tolerance in low-carbohydrate diet: maybe only a physiological state. Am J Physiol Endocrinol Metab. 2013;305(12):E1521.

[49] Kwiterovich PO Jr, Vining EP, Pyzik P, et al. Effect of a high-fat ketogenic diet on plasma levels of lipids, lipoproteins, and apolipoproteins in children. JAMA. 2003;290(7):912–920.

[50] Sumithran P, Prendergast LA, Delbridge E, et al. Ketosis and appetite-mediating nutrients and hormones after weight loss. Eur J Clin Nutr. 2013;67(7):759–764.

[51] Dumas SN, Lamming DW. Next generation strategies for geroprotection via mTORC1 inhibition. J Gerontol A Biol Sci Med Sci. 2019.

[52] Blagosklonny MV. Koschei the immortal and anti-aging drugs. Cell Death Dis. 2014;5:e1552.

[53] Roth GS, Ingram DK. Manipulation of health span and function by dietary caloric restriction mimetics. Ann N Y Acad Sci. 2016;1363:5–10.

[54] Longo KD, Fontana L. Intermittent supplementation with rapamycin as a dietary restriction mimetic. Aging (Albany NY). 2011;3(11):1039–1040.

[55] Mercken EM, Carboneau BA, Krzysik-Walker SM, et al. Of mice and men: the benefits of caloric restriction, exercise, and mimetics. Ageing Res Rev. 2012;11(3):390–398.

[56] Blagosklonny MV. Rapamycin-induced glucose intolerance: hunger or starvation diabetes. Cell Cycle. 2011;10(24):4217–4224.

[57] Blagosklonny MV. Once again on rapamycin-induced insulin resistance and longevity: despite of or owing to. Aging (Albany NY). 2012;4(5):350–358.

[58] Blagosklonny MV. TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists. Cell Death Dis. 2013;4:e964.

[59] Lamming DW, Ye L, Katajisto P, et al. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science. 2012;335(6076):1638–1643.

[60] Krebs M, Brunmair B, Brehm A, et al. The Mammalian target of rapamycin pathway regulates nutrient-sensitive glucose uptake in man. Diabetes. 2007;56(6):1600–1607.

[61] Zhou W, Ye S. Rapamycin improves insulin resistance and hepatic steatosis in type 2 diabetes rats through activation of autophagy. Cell Biol Int. 2018;42(10):1282–1291.

[62] Ueno M, Carvalheira JB, Tambascia RC, et al. Regulation of insulin signalling by hyperinsulinemia:
role of IRS-1/2 serine phosphorylation and the mTOR/p70 S6K pathway. Diabetologia. 2005;48 (3):506–518.

63. Reifsnyder PC, Flurkey K, Te A, et al. Rapamycin treatment benefits glucose metabolism in mouse models of type 2 diabetes. Aging (Albany NY). 2016;8 (11):3120–3130.

64. He S, Zhang Y, Wang D, et al. Rapamycin/GABA combination treatment ameliorates diabetes in NOD mice. Mol Immunol. 2016;73:130–137.

65. Inoki K, Mori H, Wang J, et al. mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J Clin Invest. 2011;121 (6):2181–2196.

66. Godel M, Hartleben B, Herbach N, et al. Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest. 2011;121(6):2197–2209.

67. Nagai K, Matsubara T, Mima A, et al. Gas6 induces Akt/mTOR-mediated mesangial hypertrophy in diabetic nephropathy. Kidney Int. 2005;68(2):552–561.

68. Sataranatarajan K, Mariappan MM, Lee MJ, et al. Regulation of elongation phase of mRNA translation in diabetic nephropathy: amelioration by rapamycin. Am J Pathol. 2007;171(6):1733–1742.

69. Wittmann S, Daniel C, Stief A, et al. Long-term treatment of sirolimus but not cyclosporine ameliorates diabetic nephropathy in the rat. Transplantation. 2009;87(9):1290–1299.

70. Lloberas N, Cruzado JM, Franquesa M, et al. Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J Am Soc Nephrol. 2006;17(5):1395–1404.

71. Yang Y, Wang J, Qin L, et al. Rapamycin prevents early steps of the development of diabetic nephropathy in rats. Am J Nephrol. 2007;27(5):495–502.

72. Sakaguchi M, Isozo M, Ishihik S, et al. Inhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice. Biochem Biophys Res Commun. 2006;340(1):296–301.

73. Mori H, Inoki K, Masutani K, et al. The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential. Biochem Biophys Res Commun. 2009;384(4):471–475.

74. Flauger M, Lloberas N, Franquesa M, et al. The combination of sirolimus and rosiglitazone produces a renoprotective effect on diabetic kidney disease in rats. Life Sci. 2010;87(5–6):147–153.

75. Reifsnyder PC, Doty R, Harrison DE. Rapamycin ameliorates nephropathy despite elevating hyperglycemia in a polygenic mouse model of type 2 diabetes, NONcNZO10/LtJ. PLoS One. 2014;9(12):e114324.

76. Lu MK, Gong XG, Guan KL. mTOR in podocyte function: is rapamycin good for diabetic nephropathy? Cell Cycle. 2011;10(20):3415–3416.

77. Wahl PR, Serra AL, Le Hir M, et al. Inhibition of mTOR with sirolimus slows disease progression in Han: sPRDrats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant. 2006;21:598–604.

78. Kaeberlein M. Rapamycin and ageing: when, for how long, and how much? J Genet Genomics. 2014;41 (9):459–463.

79. Dodds SG, Livi CB, Parihar M, et al. Adaptations to chronic rapamycin in mice. Pathobiol Aging Age Relat Dis. 2016;6:31688.

80. Swindell WR. Rapamycin in mice. Aging (Albany NY). 2017;9(9):1941–1942.

81. Blagosklonny MV. Disease or not, aging is easily treatable. Aging (Albany NY). 2018;10(11):3067–3078.

82. Ross C, Salmon A, Strong R, et al. Metabolic consequences of long-term rapamycin exposure on common marmoset monkeys (Callithrix jacchus). Aging (Albany NY). 2015;7(11):964–973.

83. Tortorici MA, Parks V, Matschke K, et al. The evaluation of potential pharmacokinetic interaction between sirolimus and tacrolimus in healthy volunteers. Eur J Clin Pharmacol. 2013;69(4):835–842.

84. Brattstrom C, Sawe J, Jansson B, et al. Pharmacokinetics and safety of single oral doses of sirolimus (rapamycin) in healthy male volunteers. Ther Drug Monit. 2000;22(5):537–544.

85. Mannick JB, Morris M, Hockey HP, et al. TORC1 inhibition enhances immune function and reduces infections in the elderly. Sci Transl Med. 2018;10:449.

86. Mannick JB, Del Giudice G, Lattanzi M, et al. mTOR inhibition improves immune function in the elderly. Sci Transl Med. 2014;6(268):268ra179.

87. Kraig E, Linehan LA, Liang H, et al. A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: immunological, physical performance, and cognitive effects. Exp Gerontol. 2018;105:53–69.

88. Shivashwamy V, McClure M, Passer J, et al. Hyperglycemia induced by tacrolimus and sirolimus is reversible in normal Sprague-dawley rats. Endocrine. 2010;37(3):489–496.

89. Liu Y, Diaz V, Fernandez E, et al. Rapamycin-induced metabolic defects are reversible in both lean and obese mice. Aging (Albany NY). 2014;6(9):742–754.

90. Fang Y, Westbrook R, Hill C, et al. Duration of rapamycin treatment has differential effects on metabolism in mice. Cell Metab. 2013;17(3):456–462.

91. Makki K, Taront S, Molendi-Coste O, et al. Beneficial metabolic effects of rapamycin are associated with enhanced regulatory cells in diet-induced obese mice. PLoS One. 2014;9(4):e92684.

92. Leontiev OA, Paszkiewicz G, Demidenko ZN, et al. Resveratrol potentiates rapamycin to prevent hyperinsulinemia and obesity in male mice on high fat diet. Cell Death Dis. 2013;4:e472.

93. Steven S, Lim EL, Taylor R. Population response to information on reversibility of type 2 diabetes. Diabet Med. 2013;30(4):e135–138.
[94] Steven S, Taylor R. Restoring normoglycaemia by use of a very low calorie diet in long- and short-duration Type 2 diabetes. Diabet Med. 2015;32(9):1149–1155.

[95] Steven S, Hollingsworth KG, Al-Mrabeh A, et al. Very low-calorie diet and 6 months of weight stability in type 2 diabetes: pathophysiological changes in responders and nonresponders. Diabetes Care. 2016;39(5):808–815.

[96] Taylor R. Calorie restriction for long-term remission of type 2 diabetes. Clin Med (Lond). 2019;19(1):37–42.

[97] Lean ME, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018;391(10120):541–551.

[98] Perry RJ, Peng L, Cline GW, et al. Mechanisms by which a very-low-calorie diet reverses hyperglycemia in a rat model of type 2 diabetes. Cell Metab. 2018;27(1):210–217 e213.

[99] Lips MA, van Klinken JB, Pijl H, et al. Weight loss induced by very low calorie diet is associated with a more beneficial systemic inflammatory profile than by Roux-en-Y gastric bypass. Metabolism. 2016;65(11):1614–1620.

[100] Kim G, Lee SG, Lee BW, et al. Spontaneous ketonuria and risk of incident diabetes: a 12 year prospective study. Diabetologia. 2019;62(5):779–788.

[101] Sengupta S, Peterson TR, Laplante M, et al. mTORC1 controls fasting-induced ketogenesis and its modulation by ageing. Nature. 2010;468(7327):1100–1104.

[102] Cuyas E, Fernandez-Arroyo S, Buxó M, et al. Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients. Aging (Albany NY). 2019;11(9):2874–2888.

[103] Su Y, Wang T, Wu N, et al. Alpha-ketoglutarate extends Drosophila lifespan by inhibiting mTOR and activating AMPK. Aging (Albany NY). 2019;11(12):4183–4197.